|
業務類別
|
-- |
|
業務概覽
|
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, aninvestigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI). |
| 公司地址
| 75 State Street, Suite 100, Boston, MA, USA, 02109 |
| 電話號碼
| +1 617 229-6499 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.finchtherapeutics.com |
| 員工數量
| 1 |
| Mr. Lance Thibault, C.P.A. |
Chief Financial Officer and Principal Accounting Officer |
-- |
25/03/2024 |
| Mr. Matthew P. Blischak |
Chief Executive Officer, President, and Secretary |
-- |
25/03/2024 |
|
|
| Mr. Christian Lange |
Independent Director |
25/03/2024 |
| Ms. Susan E. Graf |
Chairman of the Board |
25/03/2024 |
| Mr. Domenic Ferrante |
Independent Director |
25/03/2024 |
| Mr. Chris Shumway |
Independent Director |
25/03/2024 |
| Mr. Jeffrey A. Smisek |
Independent Director |
25/03/2024 |
|
|
|
|
